Loading...

Intellectia LogoIntellectia
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. DRIO
DRIO logo

DRIO Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • AI Stock Picker
  • Swing Trading
  • SwingMax Portfolio
  • QuantAI Alpha Pick
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • Financial AI Agent
  • AI Screener
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
10.500
Open
10.500
VWAP
9.74
Vol
20.01K
Mkt Cap
63.53M
Low
9.310
Amount
194.81K
EV/EBITDA(TTM)
--
Total Shares
6.76M
EV
68.32M
EV/OCF(TTM)
--
P/S(TTM)
1.24
DarioHealth Corp. is a global digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by data analytics, software, and personalized coaching. The Company’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Its digital therapeutic platform has been designed with a user-first strategy, focusing on the user’s needs and user experience and satisfaction. Dario Blood Glucose Monitoring Starter Kit is a pocket-sized smartphone glucometer that manages diabetes in one ultra-compact device. Dario Blood Pressure Monitoring System is a blood pressure monitoring system used to measure blood pressure, which allows it to store all its user readings in the Dario App. The Dario mobile app is a complete, cloud-based solution for personal chronic condition management.
Show More

Events Timeline

(ET)
2025-12-02
08:11:00
DarioHealth Secures 34 New Employer Clients, Exceeding 2025 Target by 98%
select
2025-11-24 (ET)
2025-11-24
08:09:25
DarioHealth Reveals Study Publication in JMIR Regarding Digital Health Platform
select
2025-11-13 (ET)
2025-11-13
06:36:29
DarioHealth announces Q3 EPS of $2.96, surpassing consensus estimate of $2.42
select
2025-10-13 (ET)
2025-10-13
08:36:20
DarioHealth adds six new employer clients to its portfolio
select
2025-09-25 (ET)
2025-09-25
06:03:34
DarioHealth launches strategic assessment following interest from potential investors.
select
2025-09-02 (ET)
2025-09-02
07:32:14
DarioHealth Secures Five New Employer Contracts for Cardiometabolic Solutions
select
2025-08-25 (ET)
2025-08-25
08:01:45
DarioHealth reveals 20-for-1 reverse stock split
select

News

PRnewswire
7.5
01-21PRnewswire
DarioHealth Surpasses 100 Scientific Studies, Enhancing Digital Health Impact
  • Research Milestone: DarioHealth announces it has surpassed 100 scientific studies, including peer-reviewed journal articles and conference abstracts, marking a significant achievement that enhances its reputation as a trusted partner for employers and health plans in digital health.
  • Industry Leadership: Dario's extensive body of research positions it among the top tier in digital health, providing a substantial number of independent third-party studies that meet the rigorous demands of self-insured employers and health plans for measurable impact, thereby boosting its market competitiveness.
  • Scientific Rigor: Chief Medical Officer Omar Manejwala emphasizes that crossing the 100-study milestone demonstrates Dario's outcomes are durable and repeatable, further solidifying its importance in value-based decision-making and driving broader adoption of digital health solutions.
  • Future Outlook: As healthcare purchasers shift towards value-based decision-making, Dario's expanding portfolio of research is expected to support its continued growth in the digital health market, likely attracting more attention from employers and health plans.
PRnewswire
3.5
2025-12-10PRnewswire
DarioHealth Launches DarioIQ™ AI Platform for Initial Hypertension Users
  • AI Platform Launch: DarioHealth introduces DarioIQ™, providing personalized guidance for hypertension users, leveraging 13 billion real-world data points, further solidifying the company's leadership in digital health.
  • User Experience Optimization: By adopting a direct-to-consumer approach, DarioIQ™ pilots in a high-impact area, ensuring transparency and trust in user interactions, thereby laying the groundwork for future expansion.
  • Technology Integration: DarioIQ™ combines three AI components—Advisor, Sentinel, and Strategist—to deliver real-time biometric interpretation and personalized interventions, enhancing user engagement and creating measurable value.
  • Strategic Development: This launch marks a significant milestone in Dario's GenAI roadmap, aiming to drive market penetration in other chronic conditions such as diabetes and weight management through continuous AI capability expansion.
Newsfilter
3.5
2025-12-04Newsfilter
DarioHealth's Digital Nudges Significantly Lower Hypertension Outcomes
  • Significant Clinical Impact: A study published by DarioHealth in JMIR Cardio shows that data-driven digital nudges lead to a statistically significant reduction of 2.09 mmHg in monthly average systolic blood pressure among high BP users three months post-intervention, compared to a 1.06 mmHg reduction in the control group, demonstrating effectiveness in improving cardiovascular health outcomes.
  • Enhanced User Engagement: The research indicates that users with higher lifestyle activity levels achieved a greater systolic blood pressure reduction of 5.27 mmHg, underscoring the additive benefits of combining behavioral engagement with digital nudges, thereby enhancing DarioHealth's competitive position in the market.
  • Cost Savings in Health: By improving hypertension control, DarioHealth's platform has the potential to reduce costs associated with cardiovascular complications, translating into measurable value for employers and healthcare systems while improving overall population health.
  • Long-term Management Capability: The findings suggest that digital interventions are not merely momentary triggers but can support sustained hypertension management, further solidifying DarioHealth's leadership in the digital health space.
PRnewswire
3.5
2025-11-24PRnewswire
DarioHealth Announces Publication of Sanofi Study in JMIR Demonstrating an Estimated $5,077 Medical Cost Savings Per Dario Digital Health Platform User Per Year
  • Study Findings: A peer-reviewed study by Sanofi and Symphony Health revealed that Dario's digital diabetes intervention platform resulted in 23% lower hospitalization rates and 26% lower healthcare charges compared to usual care for type 2 diabetes patients.

  • Engagement Impact: Increased engagement with the Dario platform was associated with fewer inpatient and emergency room events, highlighting the effectiveness of continuous digital health support.

  • Economic Validation: The study provided strong evidence that digital health interventions can significantly reduce healthcare costs and utilization, addressing key concerns of payers and employers regarding the financial impact of such solutions.

  • DarioHealth Overview: DarioHealth is a digital health company focused on chronic condition management, offering personalized interventions through a user-centric platform that aims to improve health outcomes and reduce costs for users and healthcare systems.

NASDAQ.COM
9.5
2025-11-13NASDAQ.COM
DarioHealth Corp. Reports Reduced Losses in Q3
  • Quarterly Loss: DarioHealth Corp. reported a loss of $10.47 million for the third quarter, improving from a loss of $12.33 million in the same period last year.

  • Earnings Per Share: The company's earnings per share (EPS) were -$2.96, compared to -$4.91 in the previous year.

  • Revenue Decline: Revenue for the quarter decreased by 32.5%, totaling $5.01 million, down from $7.42 million last year.

  • Financial Overview: The financial results indicate a significant reduction in losses year-over-year, despite a notable drop in revenue.

Newsfilter
3.5
2025-11-12Newsfilter
DarioHealth Unveils New Findings Showing Major Decrease in Medical Expenses for Employers Utilizing Its Digital Health Platform
  • Cost Savings from Digital Health: DarioHealth's research presented at ISPOR Europe 2025 shows significant medical cost reductions for employer members using its digital health platform, particularly among high-risk populations.

  • Integration of Technology and Coaching: The platform combines connected devices, AI-driven insights, and human coaching to improve health outcomes and reduce overall medical expenditures.

  • Real-World Evidence: This study marks Dario's first independent demonstration of its value using claims data, linking behavior change to measurable economic impact.

  • Focus on Chronic Conditions: DarioHealth's platform addresses multiple chronic conditions, aiming to disrupt traditional healthcare approaches and provide continuous, personalized care to improve user satisfaction and health management.

Wall Street analysts forecast DRIO stock price to rise
2 Analyst Rating
Wall Street analysts forecast DRIO stock price to rise
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
11.00
Averages
13.50
High
16.00
Current: 0.000
sliders
Low
11.00
Averages
13.50
High
16.00
Stifel
David Grossman
Buy
maintain
$16
AI Analysis
2025-11-14
Reason
Stifel
David Grossman
Price Target
$16
AI Analysis
2025-11-14
maintain
Buy
Reason
Stifel analyst David Grossman adjusted the firm's price target on DarioHealth to $16 from $1.25 and keeps a Buy rating on the shares. While "encouraged" by management's ability to lower expenses and continue to sign meaningful new customer relationships, the firm views the stock as unlikely to regain momentum until there are visible signs of accelerating revenue growth and a path to profitability. Following the 20-1 reverse stock split, the firm notes that its prior price target of $1.25 would have equated to $25.
TD Cowen
Hold
maintain
$11
2025-11-14
Reason
TD Cowen
Price Target
$11
2025-11-14
maintain
Hold
Reason
TD Cowen raised the firm's price target on DarioHealth to $11 from 60c and keeps a Hold rating on the shares. The company updated its model following Q3 results which showed its revenue weakness continuing but noting its strong pipeline could lead to a recovery in 2026.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for DRIO
Unlock Now

Valuation Metrics

The current forward P/E ratio for DarioHealth Corp (DRIO.O) is -0.79, compared to its 5-year average forward P/E of -2.05. For a more detailed relative valuation and DCF analysis to assess DarioHealth Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.05
Current PE
-0.79
Overvalued PE
-0.66
Undervalued PE
-3.43

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.97
Current EV/EBITDA
-3.67
Overvalued EV/EBITDA
-1.46
Undervalued EV/EBITDA
-4.48

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
3.87
Current PS
2.79
Overvalued PS
7.13
Undervalued PS
0.60

Financials

AI Analysis
Annual
Quarterly

Whales Holding DRIO

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is DarioHealth Corp (DRIO) stock price today?

The current price of DRIO is 9.4 USD — it has decreased -8.74

What is DarioHealth Corp (DRIO)'s business?

DarioHealth Corp. is a global digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by data analytics, software, and personalized coaching. The Company’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Its digital therapeutic platform has been designed with a user-first strategy, focusing on the user’s needs and user experience and satisfaction. Dario Blood Glucose Monitoring Starter Kit is a pocket-sized smartphone glucometer that manages diabetes in one ultra-compact device. Dario Blood Pressure Monitoring System is a blood pressure monitoring system used to measure blood pressure, which allows it to store all its user readings in the Dario App. The Dario mobile app is a complete, cloud-based solution for personal chronic condition management.

What is the price predicton of DRIO Stock?

Wall Street analysts forecast DRIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DRIO is13.50 USD with a low forecast of 11.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is DarioHealth Corp (DRIO)'s revenue for the last quarter?

DarioHealth Corp revenue for the last quarter amounts to 5.01M USD, decreased -32.55

What is DarioHealth Corp (DRIO)'s earnings per share (EPS) for the last quarter?

DarioHealth Corp. EPS for the last quarter amounts to -2.96 USD, decreased -59.06

How many employees does DarioHealth Corp (DRIO). have?

DarioHealth Corp (DRIO) has 196 emplpoyees as of March 05 2026.

What is DarioHealth Corp (DRIO) market cap?

Today DRIO has the market capitalization of 63.53M USD.